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As pre-exposure prophylaxis (PrEP) effectiveness is strongly linked to adherence, we 
sought to determine if certain self-report measures could be used to inform objective PrEP 
adherence. We studied participants from the TAPIR study (a multicenter randomized study 
of daily text messages to support adherence to PrEP In At-Risk), a 48-week randomized 
controlled trial of HIV-uninfected men who have sex with men (MSM) randomized 
to receive text message to support adherence versus standard of care. Self-reported 
medication adherence was assessed using several validated measures modified for PrEP. 
Objective PrEP adherence was determined through dried blood spot (DBS) measurement 
of intracellular tenofovir diphosphate (TFV-DP) and emtricitabine triphosphate (FTC-TP). 
A summary of adherence was estimated using responses to the seven adherence items 
at weeks 12 and 48 using confirmatory factor analysis. Correlations between self-report 
questions and drug concentrations were estimated with Pearson’s correlations for 
continuous outcomes and point-biserial correlations for dichotomous outcomes. Receiver 
operating characteristic (ROC) analyses were conducted to assess the performance of 
self-report measures in predicting protective or perfect TFV-DP concentrations. Of the 
369 participants who completed week 12 or 48 visits, the mean age was 35 (standard 
deviation 9 years), with 79% White, 12% Black, and 29% Hispanic. Correlations between 
self-report measures of adherence (both individual items and the adherence factor) and 
quantifiable FTC-TP and continuous TFV-DP concentrations showed that all self-report 
measures were significantly associated with these objective measures. Compared to 
a summary measure of self-reported adherence, the 4-week percent taken question 
medication recall was the only self-report item similarly or more strongly associated with 
recent adherence and long-term protective and perfect adherence at weeks 12 and 48. 
ROC analysis also showed that 4-week percent taken question had a reasonable AUC 
(0.798 at week 12 and 0.758 at week 48) in predicting protective TFV-DP concentrations. All 
single-item self-report questions assessing PrEP adherence were significantly associated 
with biomarker quantification, with the 4-week percent taken question performing best. 
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Therefore, in the absence of drug concentration measurements, a 4-week self-report 
percent taken question may be a good single-item measure of PrEP adherence.
Keywords: adherence, men who have sex with men (MSM), self-report, pre-exposure (PrEP) prophylaxis, 
pharmacologic measures
BACKGROUND
Over the last several years, HIV prevention has increasingly 
included biomedical strategies using pre-exposure prophylaxis 
(PrEP). Once daily tenofovir disoproxil fumarate/emtricitabine 
(TDF/FTC) has been shown to greatly reduce the risk of HIV 
infection in populations at risk for HIV acquisition (Grant et al., 
2010; Baeten et al., 2012; Thigpen et al., 2012; Grant et al., 2014; 
Liu et al., 2016; McCormack et al., 2016). Sub-optimal adherence 
severely undercuts its effectiveness as an HIV prevention strategy. 
In men who have sex with men (MSM), four doses or more of 
PrEP per week has been shown to confer upwards of 99% risk 
reduction (Anderson et al., 2012; Desai et al., 2017). Taking less 
than four doses per week is considered inadequate to provide 
sufficient protection against HIV infection (Grant et al., 2014; Liu 
et al., 2016; Hojilla et al., 2018). As PrEP becomes increasingly 
available in clinical settings, one of the challenges for providers 
becomes how to accurately assess PrEP adherence outside of a 
research setting.
Presently, no single “gold standard” has been ubiquitously 
adopted to assess adherence. Research studies have employed 
biomarker quantification as an objective adherence measure. 
At present, these pharmacological assays are costly, require 
specialized laboratory equipment and personnel, and take time 
to yield results; however, there is research underway to develop 
point of care immunoassays in urine that could be used as 
clinical tools (Koenig et al., 2017; Gandhi et al., 2018). Until 
real-time drug concentration testing is available, biomarker 
quantification can be used to gauge the practicality and accuracy 
of alternative methods, including self-report measures. Several 
clinical trials have determined concentration thresholds for TFV, 
FTC, and their metabolites [tenofovir-diphosphate (TFV-DP) 
and emtricitabine-triphosphate (FTC-TP)] in various biologic 
mediums that correspond to recent and long-term PrEP dosing, 
respectively (Anderson et al., 2012; Baxi et al., 2015; Wahl et al., 
2017). Unfortunately, studies analyzing the concordance between 
biomarker concentrations and other adherence methodologies 
have returned with mixed results. Device-assisted medication 
event monitoring system (MEMS)-caps (Musinguzi et al., 2016) is 
moderately correlated with drug concentrations, but they present 
unique technological challenges and are costly. Pill counting 
and medication possession ratios (i.e., pharmacy refills) have 
weaker concordance to electronic monitoring, as they assume 
all unaccounted doses were ingested and can be manipulated by 
patients. (Haberer et al., 2015).
Self-report adherence measures generally have the lowest 
concordance with drug concentrations (Amico et al., 2014; Baxi 
et al., 2015; Musinguzi et al., 2016; van der Straten et al., 2016). 
Clinical trials have often adapted self-report adherence questions 
from antiretroviral therapy (ART) research for use in PrEP, but 
the lack of a standardized method results in large variability 
of collecting adherence outcomes (Musinguzi et al., 2016). 
Moreover, subjective adherence reporting is fundamentally 
flawed. In particular, overestimation of adherence either as 
a result of social desirability or recall bias is common across 
medical disciplines and has been observed in many PrEP efficacy 
trials and demonstration projects (Amico et al., 2014; Musinguzi 
et al., 2016; van der Straten et al., 2016; Baker et al., 2018). Despite 
these limitations, self-report is a non-invasive, ecologically valid, 
low-burden method that has already been implemented in 
clinical settings. Further investigation into developing, adapting, 
and refining accurate self-report PrEP adherence measures is 
warranted (Haberer, 2016).
In this current analysis, we analyze the concordance between 
several self-report adherence questions with two pharmacologic 
drug level measures used in a PrEP demonstration project of 
MSM to identify the most accurate PrEP-appropriate self-report 
adherence measures.
METHODS
Participants and Procedures
We employed a well-characterized high-risk cohort of MSM 
enrolled in the California Collaborative Treatment Group 
(CCTG) 595 TAPIR study (A Multicenter Randomized Study 
of Daily Text Messages to Support Adherence to PrEP In 
At-Risk for HIV Individuals; NCT01761643) (Moore et al., 
2017). Participants from four Southern California medical 
centers [University of California, San Diego (UCSD); University 
of Southern California; LA Biomed at Harbor-University of 
California Los Angeles; and Long Beach Department of Health 
and Human Services] were randomly assigned to a daily text-
messaging intervention (individualized Texting for Adherence 
Building—iTAB) versus standard of care to determine the 
efficacy of iTAB on PrEP adherence.
TAPIR participants were MSM, 18 years or older, and HIV-
negative as confirmed by an antigen/antibody (Ag/Ab) assay or 
Ab assay plus HIV nucleic acid test. Additional eligibility criteria 
included having persistent elevated risk of HIV acquisition 
through condomless anal intercourse with HIV-positive men 
and/or partners of unknown status or having a recent sexually 
transmitted infection (STI) diagnosis. Over a 48-week study 
period, all participants received once-daily PrEP with TDF/FTC, 
risk reduction and adherence counseling, safety monitoring, 
and HIV/STI testing every 3 months. Data were collected 
at baseline, weeks 4, 12, 24, 36, and 48 by both confidential 
in-person interviews and computer assisted self-interview 
(CASI) instruments, which included a survey with self-report 
adherence measures. All CASI questions were answered and 
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recorded by the participant. At weeks 12 and 48, biologic markers 
of adherence were measured, described in the next section. In the 
main study, iTAB participants were more likely to have tenofovir 
drug concentrations corresponding to near-perfect adherence 
(~7 doses per week). This analysis includes the 369 TAPIR 
participants with completed study visits at weeks 12 or 48 after 
initiating PrEP.
Measures
Pre-exposure prophylaxis as a biological marker of adherence 
was determined through dried blood spot (DBS) measurement 
of intracellular TFV-DP and FTC-TP (measuring predominately 
intra-erythrocytic concentrations). Both TFV-DP and FTC-TP 
were quantified at weeks 12 and 48 using a liquid chromatography–
tandem mass spectrometry (LC-MS/MS) assay previously 
validated (Castillo-Mancilla et al., 2013). Protective TFV-DP drug 
concentrations were defined as >700 fmol/punch (~4 doses per 
week) and perfect TFV-DP drug concentrations were defined as 
>1,250 fmol/punch (~7 doses per week). FTC-TP concentrations 
were considered consistent with dosing in the last 48 h if they had 
quantifiable values.
Self-reported medication adherence was measured at all 
study visits after baseline using seven CASI questions, some 
of which were taken from the ACTG Adherence Instrument 
(Chesney et al., 2000) and other commonly used adherence 
questions (Berg et al., 2012; Wilson et al., 2014), modified to 
assess PrEP (Table 1). Each question was examined individually. 
We used CASI self-reported adherence data from weeks 12 
and 48.
Statistical Analysis
A summary of adherence was additionally estimated using 
participant responses to the seven adherence items at weeks 
12 and 48 using confirmatory factor analysis (CFA). CFA is 
a structural equation modeling technique of examining the 
relationship between observed variables and their underlying 
latent constructs. Similar to other clustering methods, CFA 
summarizes data and estimates the amount of shared variance 
between a set of variables (Jackson et al., 2009). A one-factor 
model, accounting for the correlations among all seven PrEP 
questions and capturing a single latent construct of adherence to 
PrEP that could be considered a “purer” measure of adherence 
purged of measurement error, was estimated using robust 
maximum likelihood estimation (MLR) that is robust to non-
normally distributed data (Muthén and Muthén, 1998–2015). 
Several indices of model fit were used to evaluate the fit of the 
one-factor model to the data; in particular, the Comparative Fit 
Index (CFI), the Root Mean Square Error of Approximation 
(RMSEA), and the Standardized Root Mean Square Residual 
(SRMR) were examined and guidelines for model evaluation 
were used to judge fit (i.e., CFI > 0.90, RMSEA < 0.06, and SRMR 
< 0.08 are generally regarded as indicating good-fitting models) 
(Hu and Bentler, 1999).
Associations between individual self-report questions 
assessing adherence and objective measures of adherence 
(FTC-TP and TFV-DP) were assessed using correlation analyses. 
The adherence factor and objective adherence measures were 
also correlated to obtain a measure of association between 
a summary measure of self-reported adherence and DBS 
measurements. Correlations between continuous variables were 
estimated as Pearson’s correlations while correlations between 
continuous self-report adherence measures and dichotomous 
DBS measurements were estimated as point-biserial correlations 
using robust maximum likelihood estimation (MLR). To account 
for the non-independence of observations due to participants’ 
repeated assessment, standard errors were adjusted using a 
Huber–White sandwich estimator (Huber, 1967; Muthén and 
Muthén, 1998–2015).
To identify the self-report item best assessing PrEP adherence, 
the relative strength of associations between individual self-
report items and objective adherence were compared to the 
strength of association between the summary adherence factor 
and objective measures of adherence. To do so, correlation 
coefficients were first converted into z-scores using Fisher 
Z transformations and tests of the equality of correlation 
TABLE 1 | Self-reported adherence questions and responses.
Type Questions with Possible 
Responses (number)
4-week ability Thinking about the past 4 weeks, how 
would you rate your ability to take all 
of your PrEP medications? 
Very poor, Poor, Fair, Good, Very 
Good, Excellent (6)
4-week frequency Thinking about the past 4 weeks, how 
often did you take all of your PrEP 
medications? 
None, A Little, Sometimes, Most of 
the time, All of the time (5)
4-week percent taken Thinking about the past 4 weeks, 
what percent of the time were 
you able to take all your PrEP 
medications? 
0–100%
3-month recall When was the last time you were not 
able to take your PrEP medication? 
Never, >3 months ago, 1–3 months, 
2–4 weeks, 1–2 weeks, past week (6)
1-month good job In the last 30 days, how GOOD 
A JOB did you do at taking your 
PrEP medication in the way you are 
supposed to?
Very poor, Poor, Fair, Good, Very 
Good, Excellent (6)
1-month frequency In the last 30 days, how OFTEN did 
you take PrEP medication in the way 
you are supposed to? 
Never, Rarely, Sometimes, Usually, 
Most always, Always (6)
1-month difficulty In the last 30 days, how HARD 
was it for you to take your PrEP 
medication in the way you are 
supposed to? 
Never, Rarely, Sometimes, Usually, 
Most always, Always (6)
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coefficients (i.e., comparisons associations between individual 
self-report items and biologically-quantified adherence versus 
the association between the summary adherence factor and 
biologically-quantified adherence) were carried out using 
asymptotic z-tests (Steiger, 1980; Lee and Preacher, 2013). 
Corrections for multiple comparisons were made using the 
Benjamini–Hochberg procedure at a false discovery rate of 0.25 
(Benjamini and Hochberg, 1995).
Receiver operating characteristic (ROC) analyses were also 
conducted to assess the performance of these self-report measures 
in predicting protective or perfect TFV-DP concentrations 
(Fawcett, 2006). Area under the ROC curve (AUC) was calculated 
with a 95% confidence interval. An AUC of 0.5 indicates no 
discrimination and an AUC of 1.0 indicates a perfect diagnostic 
test. Therefore, consistent with current statistical consensus, an 
AUC of < 0.7 was considered poor, 0.7 to 0.8 adequate, and 0.8 
to 0.9 very good. Factor analyses and correlational associations 
were carried out in Mplus v7.4 while ROC analyses were carried 
out using Rv3.5.1 (Muthén and Muthén, 1998–2015).
RESULTS
Of the 369 participants contributing data to these analyses, 
the mean age was 35 with a standard deviation of 9 years. The 
majority of participants were white (79%), with 12% Black and 
29% Hispanic. More than half of the participants held a bachelor’s 
or advanced degree and nearly two-thirds had a monthly income 
of $2,000 or greater. Half were in the intervention arm of TAPIR 
(Table 2).
The fit of a one-factor CFA composed of all self-report adherence 
was adequate (CFI = .946, RMSEA = .078, and SRMR = .024), 
and all adherence items had large and significant factor loadings, 
suggesting good associations with the latent adherence construct 
(Table 3) (Hu and Bentler, 1999). Correlation analyses showed 
significant associations between all self-report adherence questions 
and pharmacologic measures. Specifically, individual self-report 
items and the adherence factor were correlated with quantifiable 
FTC-TP concentrations, continuous TFV-DP concentrations, 
and TFV-DP dichotomized at protective (>700 fmol/punch) 
and perfect (>1,250 fmol/punch) concentrations. Furthermore, 
the largest correlations were consistently between the various 
self-report measures and protective levels of TFV-DP (Table 4). 
We then compared 1) the associations between self-report items 
and biologically quantified adherence versus 2) the association 
between the summary adherence factor and biologically 
quantified adherence. Results of asymptotic z-tests suggested 
that 4-week percent taken was more significantly associated 
with recent adherence (quantifiable FTC) while 4-week ability, 
4-week frequency, 3-month recall, and 1-month difficulty 
were associated with recent adherence to the same degree as 
the summary measure. The remaining self-report items had 
significantly weaker correlations. In terms of longer-term 
adherence, 4-week percent taken was associated with protective 
TFV-DP concentrations (>700 fmol/punch) to the same degree 
as the summary measure; all other measures were significantly 
less correlated than the summary measure. With regards to 
perfect TFV-DP adherence (>1,250 fmol/punch), compared with 
the summary measure, 4-week percent taken, 4-week ability, 
4-week frequency, and 3-month recall had a similar correlations. 
The remaining measures were marginally or significantly 
less correlated with perfect TFV-DP concentrations than the 
summary measure (Supplementary Table 1). When comparing 
the adherence measures with continuous concentrations of 
TFV-DP, only 4-week percent taken and 3-month recall were 
similarly associated to TFV-DP concentrations as the summary 
adherence measure. Thus, compared with a summary measure 
of self-reported adherence, the 4-week percent taken medication 
recall was the only self-report item to consistently be similarly or 
more strongly associated with recent adherence and long-term 
protective and perfect PrEP adherence at weeks 12 and 48.
Finally, we evaluated the performance of the self-report 
questions in predicting protective or perfect TFV-DP 
concentrations using ROC analyses. AUC values were calculated 
at weeks 12 and 48. Similar to findings above, ROC analyses also 
showed that 4-week percent taken question had a fairly good AUC 
(0.798 at week 12 and 0.758 at week 48) in predicting protective 
TFV-DP concentrations. However, all self-reported measures 
were not particularly good for predicting perfect TFV-DP (AUC 
all below 0.7). Results from week 48 are displayed in Figure 1.
DISCUSSION
We found that all single-item self-report questions assessing 
PrEP adherence were significantly associated with biomarker 
quantification with the 4-week percent taken question performing 
best. In addition, the 4-week percent taken question had a reasonable 
AUC value in predicting protective TFV-DP concentrations at 
both weeks 12 and 48. Therefore, in the absence of drug level 
measurements, our findings suggest that a 4-week self-report 
percent taken question may be a good single-item measure of both 
recent and cumulative adherence.
Several recent studies have similarly examined different 
combinations of subjective and objective PrEP adherence 
TABLE 2 | Participant demographics and sample characteristics. 
Characteristic Descriptive statistic
Age, mean (SD) 35 (9)
Education, n (%)
 High school or Less 24 (7%)
 Some college 137 (37%)
 Bachelors 130 (35%)
 Some post-graduate 18 (5%)
 Advanced degree 60 (16%)
Race and ethnicity, n (%)
 White 292 (79%)
 Black 44 (12%)
 Hispanic 105 (289%)
Income, n (%)
 <$2,000 per month 76 (21%)
 ≥$2,000 per month 238 (65%)
Intervention arm, n (%) 182 (49%)
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measures and have found varying degrees of concordance among 
them. In the TDF2 clinical trial of men and women in Botswana, 
self-report adherence via an interview question assessing missed 
doses over the last 3 days was only modestly associated with 
quantifiable drug concentrations of tenofovir (TFV) and FTC 
quantified in plasma (Kebaabetswe et al., 2015). Similar results 
were observed in serodiscordant couples in East Africa where 
three types of self-reported adherence questions were not able 
to discriminate between steady-state daily dosing and less than 
steady-state daily dosing plasma TVF concentrations (Musinguzi 
et al., 2016). Within the preexposure prophylaxis initiative 
(iPrEx) trial, there were differences in consistency between 
self-report and PrEP drug detection by study site with good 
concordance in the US but large discrepancies in subjective and 
objective measures in non-US study sites. Self-reported recent 
PrEP dosing using neutral interviewing was a strong predictor 
of TFV quantitation in plasma in the iPrEX open-label extension 
(OLE) (Amico et al., 2016). Our study is an important addition 
to this literature because it 1) examines several self-report items 
assessing different aspects of adherence behavior and duration 
of recall, 2) employs unique statistical methods using latent 
constructs to develop a theoretical adherence measure without 
measurement errors, 3) evaluates recent and cumulative PrEP 
adherence using DBS quantification, and 4) includes continuous 
and dichotomous outcomes of objective adherence.
Because PrEP efficacy highly depends on medication 
adherence, it is frequently studied in HIV prevention research and 
evaluated in PrEP clinical care. Subjective adherence reporting 
is the most commonly used method to quantify adherence 
behavior in real time (Agot et al., 2015). As is true for self-report 
of medication adherence in general (Stirratt et al., 2015), there is 
no standard self-report adherence measure of PrEP used across 
research studies or clinical practice. A large number and wide 
variety of self-report adherence measures have already been 
adapted or developed to quantify PrEP adherence (Muchomba 
et al., 2012). As a result, it may be difficult to evaluate or compare 
PrEP adherence self-report in a systematic way due to lack 
of inconsistency in measures used. Across several large PrEP 
clinical trials, there was minimal overlap of self-report questions 
used to evaluate adherence (Amico et al., 2014; Agot et al., 2015; 
Kebaabetswe et al., 2015; Amico et al., 2016; Musinguzi et al., 
2016). Differences in how questions are framed, what period is 
used, and which response options are offered may affect how 
adherence is reported and thus measured. Having a least one self-
report measure of adherence that is widely utilized and perhaps 
recommended in guidelines or expert options could improve 
research findings and clinical outcomes through harmonization 
of subjective adherence assessment.
PrEP delivery in limited resource locations necessitates 
inexpensive and easy approaches to offer and monitor PrEP. As 
self-report may be the sole method to measure PrEP adherence, a 
question that is both sensitive and specific could offer an accurate 
appraisal of adherence and help direct resources to those needing 
additional adherence support in well-resourced but high-volume 
PrEP clinics. Using a single question that elicits a response best 
reflecting real adherence behavior is an efficient way to gauge 
adherence. In addition, one adherence question could be included 
in clinic intake forms that patients can answer more privately, 
potentially reducing social desirability bias (Bowling, 2005).
While our study had several strengths including a large 
sample size and assessments performed at multiple time points, 
there are some limitations. Since our study included only MSM 
in a resource-rich setting, our results may not be generalizable 
to other at-risk populations or those in resource-limited settings 
taking PrEP. Study timing may have significantly influenced 
our findings, as it was conducted soon after the FDA approval 
TABLE 3 | Factor indicators and loadings in a one-factor model of adherence.
Indicator Standardized loading Standard error
4-week ability 0.908*** 0.027     
4-week frequency 0.869***    0.027     
4-week percent taken 0.842***     0.021
3-month recall (reversed) 0.551*** 0.033    
1-month good job 0.910*** 0.022     
1-month frequency 0.893*** 0.027     
1-month difficulty 0.651*** 0.050     
TABLE 4 | Correlations between pharmacological and self-report adherence measures.
Adherence measures aFTC-TP bTFV-DP aTFV-DP ≥ 700 fm/p aTFV-DP ≥ 1250 fm/p
Summary self-report 
(adherence factor)
0.252*** 0.360*** 0.465*** 0.262***
4-week ability 0.239*** 0.317*** 0.424*** 0.237***
4-week frequency 0.215*** 0.309*** 0.384*** 0.234***
4-week percent taken 0.324*** 0.372*** 0.439*** 0.251***
3-month recall (reversed) 0.169** 0.283*** 0.296*** 0.239***
1-month good job 0.177** 0.305*** 0.338*** 0.235***
1-month frequency 0.187** 0.299*** 0.380*** 0.189***
1-month difficulty 0.173** 0.209*** 0.272*** 0.168***
**0.05>p>0.001; ***p<0.001; 
FTC-TP, emtricitabine triphosphate; TFV-DP, tenofovir diphosphate; fm/p, fmol/punch.
aCorrelations using dichotomous pharmacological measures of adherence are point-biserial correlations.
bCorrelations using continuous pharmacological measures of adherence are Pearson correlations.
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of PrEP. We had many early adopters who had high overall 
adherence based on DBS concentrations and were less likely to 
overestimate adherence. In addition, we only used single-item 
adherence questions to evaluate associations with PrEP drug 
concentrations. Some questions were designed to be asked as part 
of a group so alone they may have less intrinsic value. Finally, 
there are other commonly used self-report questions, which may 
be similarly or better correlated with biological measurements, 
not included in our study.
CONCLUSIONS
Self-report questions to measure PrEP adherence are commonly 
utilized in clinical research and may be the only method deployed 
to assess medication adherence. It is essential to better understand 
which subjective measures are most accurate and how they can 
effectively be integrated into PrEP research and clinical care. Our 
findings demonstrate that a 4-week percent taken question of 
medication recall may best reflect true recent and longer-term 
adherence behavior. In the future, we will explore combinations 
of different self-report adherence questions that may yield even 
stronger associations with PrEP drug concentrations.
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